- Home
- CMDB vs CERS Comparison
CMDB vs CERS Comparison
Compare CMDB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMDB
- CERS
- Stock Information
- Founded
- CMDB 2023
- CERS 1991
- Country
- CMDB Monaco
- CERS United States
- Employees
- CMDB N/A
- CERS N/A
- Industry
- CMDB
- CERS EDP Services
- Sector
- CMDB
- CERS Technology
- Exchange
- CMDB Nasdaq
- CERS Nasdaq
- Market Cap
- CMDB 222.7M
- CERS 255.0M
- IPO Year
- CMDB N/A
- CERS 1997
- Fundamental
- Price
- CMDB $11.98
- CERS $1.23
- Analyst Decision
- CMDB
- CERS Strong Buy
- Analyst Count
- CMDB 0
- CERS 2
- Target Price
- CMDB N/A
- CERS $3.50
- AVG Volume (30 Days)
- CMDB 93.5K
- CERS 1.1M
- Earning Date
- CMDB 11-12-2025
- CERS 10-29-2025
- Dividend Yield
- CMDB N/A
- CERS N/A
- EPS Growth
- CMDB N/A
- CERS N/A
- EPS
- CMDB N/A
- CERS N/A
- Revenue
- CMDB $799,159,000.00
- CERS $192,510,000.00
- Revenue This Year
- CMDB N/A
- CERS $22.02
- Revenue Next Year
- CMDB N/A
- CERS $9.32
- P/E Ratio
- CMDB N/A
- CERS N/A
- Revenue Growth
- CMDB 152.53
- CERS 13.25
- 52 Week Low
- CMDB $8.46
- CERS $1.12
- 52 Week High
- CMDB $12.42
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- CMDB N/A
- CERS 45.54
- Support Level
- CMDB N/A
- CERS $1.17
- Resistance Level
- CMDB N/A
- CERS $1.27
- Average True Range (ATR)
- CMDB 0.00
- CERS 0.06
- MACD
- CMDB 0.00
- CERS -0.00
- Stochastic Oscillator
- CMDB 0.00
- CERS 33.33
About CMDB Costamare Bulkers Holdings Limited Common Stock
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.